Thrombocytopenia
Conditions
Interventions
Patients who received romiplostim N01 after HSCT:None
Patients who did not receive romiplostim N01 after HSCT:None
Sponsors
Wuhan Childrens Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or younger; 2. Diagnosed with a hematological disease and undergoing HSCT; 3. Developing post-transplant thrombocytopenia, defined as a platelet count of less than 50×10^9/L lasting for at least one week, or presenting with bleeding symptoms caused by thrombocytopenia; 4. Patient or their legal representative signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergy to romiplostim N01 or its excipients; 2. Combined with severe hepatic or renal dysfunction (e.g., transaminase levels exceeding 3 times the upper limit of normal, creatinine clearance less than 30 mL/min); 3. Presence of uncontrolled infectious diseases; 4. Previous splenectomy (as this surgery may affect platelet metabolism and interfere with study results); 5. Expected survival time of less than 3 months (unable to complete full treatment and follow-up).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Coagulation function; | — |
Countries
China
Contacts
Public ContactXiong Hao
Wuhan Childrens Hospital
Outcome results
None listed